NT Pharma Group

What NT Pharma Group does

NT Pharma Group (中国泰凌医药集团有限公司, stock code 01011.HK) is a Hong Kong-listed pharmaceutical group founded in 1995 that originally built its business as China's largest comprehensive vaccine supply chain and promotion service provider, historically holding 23.4% of the Category II vaccine market and directly covering approximately 79% of China's disease prevention and control centers and 72% of city immunization points. After its 2011 HKEX IPO underwritten by UBS and Goldman Sachs, the company pivoted into an integrated pharmaceutical enterprise focused on orthopedics, psychiatry, hepatology, and oncology, and from 2020 onward consolidated its strategy around bone health through a RMB 900 million joint venture with Kangchen Pharmaceutical (Beijing Kangchen Biotechnology) and the 2023 launch of the Fu Aimeng 4M Bone Health Digital Medical Service Platform.

The company's commercial backbone consists of the Miacalcic brand (salmon calcitonin injection and nasal spray, originally developed by Novartis and FDA-approved), which Beijing Kangchen now markets and which is positioned as the only drug approved by China's NMPA for preventing acute and progressive bone loss. NT Pharma has also acquired exclusive commercial rights to Otelixizumab (one of the world's top 10 new drugs, in US Phase 2) and to Pfenex's Teriparatide biosimilar across Greater China and Southeast Asia, and owns full IP and manufacturing for the National Category 1 new drug Xidike through Tailing Biological Pharmaceutical Jiangsu. The Fu Aimeng platform integrates four modules — drug supply (骨病药物治疗), cross-border bone health products (跨境骨健康产品), medical device/rehabilitation (器械/康复), and digital medicine services (数字医药服务平台) — into a closed-loop ecosystem serving osteoporosis and bone disease patients across pre-care, hospital, and post-discharge phases.

The group generates revenue through pharmaceutical product sales (Miacalcic and legacy distribution), a sales-led model anchored on academic promotion and direct sales teams covering 20,000+ grassroots medical institutions and 300+ domestic partners, digital medical platform services including patient management and online/offline bone health consulting stations, cross-border e-health product supply through online public/private platforms and offline retail, and medical device and rehabilitation services. The Beijing Kangchen JV alone generates over RMB 300 million in annual sales revenue. NT Pharma employs 150-200 people in the JV's overseas operations (Germany, France, Hong Kong), and the company has operations across mainland China, Hong Kong, Singapore, Malaysia, Thailand, Germany, and France. Strategic capital partners have included TPG (2008 strategic investment) and the JV partner Kangchen Pharmaceutical.

Name

NT Pharma Group

Legal name

中国泰凌医药集团有限公司

Website

https://ntpharma.com

Company type

Public

Founded year

1995

Operating status

Operating

Headcount range

501–1,000 employees

Short description

NT Pharma Group (01011.HK) is a Hong Kong-listed pharmaceutical company that pivoted from China's largest vaccine distribution network into an integrated bone health platform. It markets the Miacalcic brand (salmon calcitonin from Novartis), the Fu Aimeng 4M digital bone health platform, and acquired pipeline assets including Otelixizumab and Teriparatide biosimilar across Greater China and Southeast Asia.

Ownership category

akta.pro rank

Product category

Bone Health Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (42421), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Services-Health Services (8000)

akta.pro primary industry

Specialty Pharmacy & Complex Therapy Management Platforms (HLACAKAG)

akta.pro secondary industries

Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD), Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

Keywords

• Bone health pharmaceuticals
• Osteoporosis treatment
• Pharmaceutical distribution
• Digital medical platform
• Vaccine distribution services

Headquarters

HQ city

Shanghai

HQ country

China

HQ region

Asia

Offices7 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Marketing or Sales, Technology or R&D, Operations

Revenue model

1. Pharmaceutical Product Sales: Revenue from sales of proprietary and licensed pharmaceutical products including Miacalcic (salmon calcitonin injection and nasal spray), covering osteoporosis treatment and acute bone loss prevention.
2. Bone Health Digital Platform Services: Revenue from digital medical platform services including patient management, cross-border personalized procurement, and online/offline bone health consulting stations.
3. Cross-border E-Health Product Supply: Revenue from importing and distributing international bone health products including pharmaceuticals, medical devices, and health supplements through cross-border channels for online public/private platforms and offline sales.
4. Medical Device and Rehabilitation Services: Revenue from intelligent home rehabilitation equipment, medical device distribution, and chain of bone health consulting stations providing integrated orthopedic health consultation services.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

NT Pharma Group is an integrated pharmaceutical and digital health company focused on bone health. It distributes and licenses proprietary pharmaceuticals including the FDA-approved Miacalcic salmon calcitonin brand (acquired from Novartis), and operates the Fu Aimeng 4M Bone Health Digital Medical Service Platform that integrates drugs, cross-border e-health products, medical devices/rehabilitation, and AI-driven patient management into a closed-loop ecosystem serving 20,000+ grassroots medical institutions and 300+ domestic partners across China and select Southeast Asian markets.

Product overview

NT Pharma Group is a diversified pharmaceutical company that has evolved from a vaccine distributor and promotion service provider into an integrated pharmaceutical enterprise focused on bone health. The company's product portfolio centers on the '福艾蒙' (4M) digital medicine service platform, which integrates four service modules: bone disease medication, cross-border bone health products, medical devices/rehabilitation, and digital medicine platform. Key products include the acquired '密盖息' (Miacalcic) brand of salmon calcitonin injections and nasal sprays for osteoporosis treatment, the pipeline drug Otelixizumab in Phase 2 clinical trials, and the joint venture Beijing Kangchen Bio focused on bone health services. The company also holds intellectual property and manufacturing for drugs like Xidike and holds exclusive commercial rights to Teriparatide biosimilar in Greater China and Southeast Asia.

Differentiator

Problem solved

Functional benefit

Products and services

• Miacalcic Salmon Calcitonin Injection (密盖息® 鲑降钙素注射液) Salmon calcitonin injectable for osteoporosis treatment, osteoporotic pain, and prevention of acute bone loss. Inhibits osteoclast activity, reduces osteoclast count, decreases bone loss while increasing bone mass, with dual analgesic mechanism. Marketed to physicians treating osteoporosis and other bone diseases.
• Miacalcic Salmon Calcitonin Nasal Spray (密盖息® 鲑降钙素鼻用喷雾剂) Salmon calcitonin nasal spray absorbed via nasal mucosa capillaries; treats various osteoporosis, osteoporotic pain, and prevents acute bone loss with dual analgesic mechanism.
• Xidike Urinary Polypeptide Injection (喜滴克® 尿多酸肽注射液) National Category 1 new drug injectable for which NT Pharma holds all intellectual property rights and the manufacturing facility, operated under NT Pharma Biologics Jiangsu.
• Teriparatide Biosimilar (特立帕肽生物仿制药) Teriparatide biosimilar licensed from Pfenex (USA); NT Pharma holds permanent exclusive commercial rights in mainland China, Hong Kong, Thailand, Singapore, and Malaysia for osteoporosis treatment.
• Otelixizumab (奥替单抗) One of the world's top 10 new drugs; therapeutic applications include myocardial infarction, atherosclerosis, psoriasis, rheumatoid arthritis, psoriatic arthritis, and systemic lupus erythematosus. Projected revenue exceeding RMB 1 billion per indication post-2026 China launch.
• Songzhi Wan (松栀丸) Pharmaceutical product marketed by Tailing Pharmaceutical (Changsha) Co., Ltd., a wholly-owned NT Pharma subsidiary.
• Fu Aimeng 4M Bone Health Digital Medical Service Platform (福艾蒙4M-骨健康数字医药服务平台) Integrated bone health digital medicine service platform combining four modules — (1) bone disease drug supply (Medicine), (2) cross-border bone health product procurement (Multinational E-Health), (3) medical devices and rehabilitation (Medical Device), and (4) AI-powered digital medical services (Medical Digital Platform) — providing closed-loop management across pre-care, in-hospital, and post-discharge phases. Supports chronic disease patient follow-up, cross-border personalized product supply, online/offline bone health consulting stations, and academic promotion resources for distributors.

Quantifiable outcome

• Otelixizumab projected to generate over RMB 1 billion in sales per indication post-2026 China launch
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature2 records

Partnerships

Six partnerships are on record, tiered core and minor.

• 北京康辰药业 (Beijing Kongrun Pharmaceutical Co., Ltd.)coreStrategic or Co-development Partner · 1 January 2020NT Pharma and Kongrun Pharmaceutical jointly invested RMB 900 million to establish Beijing Kongrun Biotechnology in 2020 (operational from 2021). The joint venture focuses on building a leading bone health service platform around the Miacalcic brand, covering bone disease treatment across all levels of medical institutions in China. Kongrun holds majority stake; NT Pharma is a minority shareholder.
• Pfenex (USA)minorStrategic or Co-development Partner · 1 January 2018NT Pharma obtained permanent exclusive commercial rights for Teriparatide biosimilar in China mainland, Hong Kong, Thailand, Singapore, and Malaysia from US-based Pfenex in 2018.
• 葛兰素史克 (GSK)minorStrategic or Co-development PartnerGSK was one of NT Pharma's major international pharmaceutical partners, with NT Pharma serving as GSK's distribution and promotion partner in China during the first decade of operations.
• 辉瑞 (Pfizer)minorStrategic or Co-development PartnerPfizer was one of NT Pharma's key international pharmaceutical partners, established during the company's rapid development phase in 2001.
• 赛诺菲巴斯德 (Sanofi-Pasteur)minorStrategic or Co-development PartnerSanofi-Pasteur was a major international partner for NT Pharma, primarily in the vaccine distribution and promotion business.
• 诺华 (Novartis)minorStrategic or Co-development PartnerNovartis developed and originally owned the Miacalcic brand (salmon calcitonin), which was later acquired by Kongrun Pharmaceuticals and is now managed through NT Pharma's joint venture. NT Pharma also acquired commercial rights to otelixizumab from Novartis.

Scale indicators12 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• UCB: UCB is a global bone-health player (Evenity/Romosozumab). Comparable as a broad incumbent in the osteoporosis therapeutic category relevant to NT Pharma's franchise.
• Amgen: Amgen is the global leader in bone-health biologics (Prolia/XGEVA - denosumab). Comparable as a broad incumbent whose bone-health franchise defines the therapeutic category NT Pharma's Miacalcic and pipeline assets compete within.
• Novartis: Novartis is the originator of the Miacalcic brand now managed through NT Pharma's Beijing Kongrun JV, and also the originator of Otelixizumab. Comparable as a broad incumbent and key licensor of NT Pharma's flagship bone-health asset.
• Sanofi: Sanofi was one of NT Pharma's major historical international partners (Sanofi-Pasteur for vaccine distribution and promotion in China). Comparable as a broad incumbent and former distribution partner with overlapping vaccine and specialty pharma interests.
• CSPC Pharmaceutical Group: CSPC Pharmaceutical Group (石药集团, 1093.HK) is a major HK-listed Chinese pharmaceutical company with bone-health and chronic-disease products. Comparable as a broad Chinese pharma incumbent with overlapping therapeutic categories and HKEX listing profile.
• Jiangsu Hengrui Medicine: Jiangsu Hengrui Medicine (600276.SH) is China's largest innovative pharmaceutical company. Comparable as a broad incumbent in branded pharmaceuticals with manufacturing scale and pipeline depth that contrasts with NT Pharma's distribution-led model.
• Sino Biopharmaceutical: Sino Biopharmaceutical (中国生物制药, 1177.HK) is one of the largest HK-listed Chinese pharma companies with a diversified specialty pharma portfolio. Comparable as a broad incumbent operating across multiple therapeutic areas from a Hong Kong listing base.
• Merck & Co. Merck & Co. is a historical bone-health incumbent (Fosamax/alendronate). Comparable as a broad incumbent whose osteoporosis franchise has shaped the China market in which NT Pharma's Miacalcic competes.
• Eli Lilly: Eli Lilly is a global leader in bone-health therapeutics (Forteo/Teriparatide, Evista). Comparable as the originator of the Teriparatide molecule that NT Pharma has licensed in biosimilar form from Pfenex, and as the dominant global player in osteoporosis treatment.

Direct peers

• Kangchen Pharmaceutical: Kangchen Pharmaceutical (康辰药业, 603590.SH) is the controlling JV partner of Beijing Kongrun Biotechnology, NT Pharma's core bone-health entity. Kangchen shares direct overlap in bone-disease therapeutics (Miacalcic franchise) and is the most directly comparable peer due to the structural JV relationship.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/china-nt-pharma-group-co-ltd

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries12 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NT Pharma Group